#United States #New York #Dry Eye #Novoxel #Tixel

Dr. Noaman Sanni and the Tixel® Revolution in Dry Eye Treatment

In recent developments within ophthalmology, Dr. Noaman Sanni, CEO of Center for Sight New York, has made headlines by incorporating the Tixel® device into his practice. This innovative technology has not only enhanced treatment options for patients suffering from dry eye but also led to impressive growth in patient numbers and clinic revenues.

The Impact of Tixel® on Dry Eye Treatment

Tixel® is a cutting-edge FDA-cleared device that leverages patented Thermo-Mechanical Action® (TMA) to address Meibomian Gland Dysfunction, a prevalent cause of dry eye. Remarkably, it performs effective treatments in under two minutes, making it a quick and efficient option for both patients and practitioners.

Dr. Sanni reports that, in a mere two-month period, his team successfully treated over 225 patients using Tixel®. The feedback from patients has been overwhelmingly positive, emphasizing improvements in eye comfort and overall quality of life.

He states, "We were not really focused on the business aspect, as our primary goal was always to prioritize medical care and patient welfare. Thus, the rapid acceptance of Tixel® amongst patients and the subsequent financial growth came as a surprise."

Clinical Validation

The efficacy of Tixel® is not simply anecdotal; it is backed by robust clinical data. A pivotal trial demonstrated significant improvements, including:

• - Tear Break-Up Time (TBUT): Participants showed marked improvements from severe dry eye conditions to the normal physiological range, sustained for up to 6 months.
• - Meibomian Gland Score (MGS): An increase of over 17 points was observed, comparable to other leading thermal pulsation systems.
• - Ocular Surface Disease Index (OSDI): Scores decreased by more than 21 points, indicating a notable enhancement in patients' quality of life.

Importantly, no adverse effects related to the device were reported, further solidifying its standing as a reliable treatment option.

Physician Endorsement

The endorsements from fellow healthcare professionals highlight Tixel®'s potential. Dr. Debra Koloms, the Medical Director at Center for Sight, emphasized the transformation in her own treatment experience, stating, "After just two Tixel® treatments, I no longer require punctal plugs or drops. This method stands out as the most effective remedy I have encountered in my 40 years of practicing medicine."

With a commitment to patient-centered care, the Center for Sight New York now offers consultations and previews of Tixel® treatments, welcoming inquiries from individuals seeking solutions for dry eye conditions. The team emphasizes educating patients about the benefits of this new technology, aiming to make significant improvements to their vision and comfort.

About Novoxel

The Tixel® device is produced by Novoxel Ltd., a company focusing on scientific advancements and clinical innovation. Established in 2011, Novoxel has secured numerous patents globally, demonstrating its commitment to deliver non-invasive and radiation-free treatment options. Their products, including Tixel®, require minimal downtime and provide less painful experiences without the need for expensive consumables.

For more information on Tixel® and its promise for dry eye treatments, visit novoxel.com.

About Center for Sight New York

Founded in the 1940s, Center for Sight is one of Northern New York's most trusted eye care practices, with comprehensive services offered in Watertown and Ogdensburg. Under Dr. Sanni's guidance since 1995, the practice has prioritized advanced treatments and state-of-the-art diagnostics, improving the quality of life for its patients. With a team of experienced ophthalmologists and technicians, their mission is to provide exceptional vision care tailored to individual patient needs.

For those struggling with dry eye symptoms, seeking consultation at Center for Sight could mark the beginning of a new chapter in their eye health journey.